About this trial
The PANENCA trial aims to reduce postoperative complications in patients undergoing pancreatoduodenectomy (also known as a Whipple procedure), a complex surgical operation performed to remove tumors located in or near the head of the pancreas. One of the most frequent and serious complications after this surgery is postoperative pancreatic fistula (POPF), a leakage of pancreatic fluid from the surgical connection. POPF can lead to intra-abdominal infection, bleeding, and inflammation, often resulting in delayed recovery and postponement of subsequent oncological treatment. In severe cases, these complications may be life-threatening.
Patients with a small main pancreatic duct (3 millimeters or less) are known to have a substantially higher risk of developing POPF. Previous studies have shown that several existing interventions may reduce the risk or severity of these complications. These include hydrocortisone, a medication that suppresses postoperative inflammation; octreotide, a medication that reduces the production of pancreatic secretions; and a surgical technique known as the ligamentum teres hepatis patch, which uses the patient's own tissue to protect nearby blood vessels in the event of a pancreatic leak.
Because the development of pancreatic fistulas is multifactorial, the investigators hypothesize that a combined approach targeting different underlying mechanisms may provide a complementary and more effective protective effect than any single intervention alone. The PANENCA trial therefore evaluates whether the combined use of hydrocortisone, octreotide, and the ligamentum teres patch can reduce the rate of major postoperative complications after pancreatoduodenectomy.
Patients participating in the study are randomly assigned to receive either the combination treatment in addition to standard perioperative care or standard perioperative care alone. The study medications are administered only during the first postoperative days, and the surgical patch is applied during the operation itself. No additional tests, monitoring procedures, or hospital visits are required beyond routine clinical care.
This international, multicenter randomized trial includes patients at high risk for POPF who are undergoing pancreatoduodenectomy. The primary objective is to determine whether the combination treatment reduces the incidence of major postoperative complications. If proven effective, this bundle approach may be implemented more consistently across participating countries and incorporated into international clinical guidelines for pancreatic surgery.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Elective pancreatoduodenectomy for any indication (both minimally invasive and open)
Pancreatic duct diameter ≤ 3mm on preoperative CT or MRI*
18 years of age or older
Signature of informed consent
Disqualifiers
Age < 18 years
Pregnancy or current breastfeeding
Known allergy or hypersensitivity to hydrocortisone or octreotide
Systemic fungal infection
Trial design
Parallel
Treatments tested in this trial
HOP bundle
Combination productPatients in the intervention group will receive the HOP bundle approach: * Hydrocortisone intravenous: 100mg hydrocortisone as sodium succinate i.v. starting during the induction of general anesthesia, administered every 8 hours until 2 days perioperative (last dose evening postoperative day 2) (total 9 dosages). * Octreotide subcutaneous: 0,1 mg every 8 hours during maximum 7 days, starting during the induction of general anesthesia, administered minimal 1 hour before surgery (to a maximum of 21 dosages or until earlier discharge). * Intraoperative coverage of the gastroduodenal artery stump using a teres ligament patch, separating it from the pancreato-enteric anastomosis.
Treatment groups
Trial outcomes
Primary outcomes
Major complications
Rate of Major Complications, defined as a Clavien-Dindo score of ≥III and/or postoperative abdominal drain placement
Secondary outcomes
Postoperative Pancreatic Fistula (POPF)
Rate of POPF grade B/C
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Lead sponsor
Erasmus Medical Center
Collaborator
UMC Utrecht
Collaborator
Medisch Spectrum Twente
Collaborator
Jeroen Bosch Ziekenhuis
Collaborator
Maastricht University Medical Center
Collaborator
Radboud University Medical Center
Collaborator
Isala
Collaborator
Catharina Ziekenhuis Eindhoven
Collaborator
Helsinki University Central Hospital
Collaborator
Oslo University Hospital
Collaborator
Karolinska University Hospital
Collaborator
Sahlgrenska University Hospital
Collaborator
University Hospital, Linkoeping
Collaborator
Lund University Hospital
Collaborator
Azienda Ospedaliera Universitaria Integrata Verona
Collaborator
Azienda Ospedaliera di Padova
Collaborator
San Raffaele University Hospital, Italy
Collaborator
Leiden University Medical Center
Collaborator
University Medical Center Groningen
Collaborator
Clinical Cancer Hospital, Kyiv
Collaborator
Rigshospitalet, Denmark
Collaborator
University Hospital, Antwerp
Collaborator